The Newest in Energy-Based Devices to Treat and Prevent Keratinocyte Cancer

In a presentation on energy-based devices for treating and preventing keratinocyte cancers, Dr. Haderstahl outlined the growing prevalence of these cancers, emphasizing the need for innovative, less invasive treatments. Annually, approximately 3.5 million cases are diagnosed in the US, with basal cell carcinoma being the most common type. The talk provided an overview of various energy-based modalities, including vascular lasers and ablative therapies, highlighting their ability to target tumors and enhance drug delivery. Dr. Haderstahl is particularly focused on laser-assisted drug delivery methods, utilizing combined therapies to improve treatment outcomes. Significant research has shown that combining fractional lasers with photodynamic therapy (PDT) can lead to enhanced drug uptake and effective clearance rates for basal cell carcinomas. Additionally, new avenues in integrating immune response stimulation and topical application of systemic therapies like PD-1 inhibitors were discussed, showcasing progress toward reducing systemic side effects of cancer treatments. Evidence indicating that energy-based devices can prevent skin cancers by removing damaged cells and modulating immune activity was also presented. The future of skin cancer management appears promising with energy-based treatments gaining traction in the medical community, potentially providing patients with effective and less invasive options in their fight against skin cancers.